COLO B: New CEO And Reset P/E Will Support Future Multiple Re Rating

The analyst price target on Coloplast has been reduced from DKK 551.68 to DKK 500.15, as analysts incorporate a series of recent target cuts and mixed ratings while adjusting assumptions around the discount rate, revenue growth, profit margins, and future P/E expectations.

Analyst Commentary

Recent Street research on Coloplast has centered on a series of target cuts and rating changes that feed directly into the revised average price target. While the direction of individual calls varies, the common thread is a reset of expectations around valuation, execution risk, and growth assumptions.

Bullish Takeaways

Bullish analysts highlight that, even with target cuts, updated models still support value above current levels on their assumptions. They point to what they see as a more balanced risk reward after the reset.
The recent upgrade at UBS signals that some see the prior de-rating as sufficient. Revised targets are intended to better align P/E expectations with the company’s current profile rather than write off its long term growth potential.
Supportive views tend to frame the lower targets as a normalization of valuation inputs, such as discount rates and margin expectations, rather than a wholesale change in the fundamental outlook.
For long term oriented investors, the spread between higher and lower targets can be read as evidence that there is still debate around upside, not just concern over downside.

Bearish Takeaways

Bearish analysts have issued multiple target cuts, including reductions by DKK 117, DKK 110, DKK 74 and other smaller trims. These collectively feed into the lower average target of DKK 500.15 and signal more cautious valuation frameworks.
Downgrades from firms such as Goldman Sachs and Nordea indicate that some see execution and growth assumptions as too optimistic at prior target levels. This has prompted them to mark down forecasts and risk premiums.
Several target changes, including moves from DKK 660 to DKK 504 and additional reductions, suggest that some analysts are reassessing what they are willing to pay for the stock’s earnings profile, particularly around future P/E expectations.
The clustering of target cuts within a relatively short period points to a period of recalibration, where bearish analysts appear more focused on protecting against downside risk than on chasing potential upside.

What’s in the News

Coloplast received an Innovative Technology contract for Biatain Silicone Fit from Vizient, following evaluation by Vizient’s client-led hospital expert councils under its Innovative Technology Program (Key Developments).
Vizient, which manages a portfolio representing more than US$140b in annual purchasing volume across a broad hospital and healthcare provider base, signaled that Biatain Silicone Fit has qualities that may improve clinical care, patient or healthcare worker safety, or business operations (Key Developments).
Coloplast revised earnings guidance for fiscal year 2025/26 and now expects reported revenue growth in DKK at around 3%, compared with previously around 4%. This reflects a lowered organic growth outlook and a 2% to 3% negative currency impact, from previously around 3% (Key Developments).
EBIT growth in constant currencies before special items for 2025/26 is now expected at around 5%, from around 7% previously. This assumes a Kerecis EBIT margin of around 0%, from around double digit previously (Key Developments).
The board appointed Gavin Wood as President and CEO of Coloplast Group effective May 1, 2026. He will succeed interim CEO Lars Rasmussen. Wood brings two decades of leadership roles at Johnson & Johnson and prior senior roles at Mölnlycke (Key Developments).

Valuation Changes

Fair Value changed from DKK 551.68 to DKK 500.15, indicating a moderate reduction in the central price target level used by analysts.
Discount Rate changed from 6.60% to 6.31%, a small adjustment that slightly changes how future cash flows are weighed.
Revenue Growth changed from 6.41% to 6.25%, a marginally lower assumption for future DKK revenue expansion.
Net Profit Margin changed from 20.23% to 20.20%, reflecting a very small refinement in expected profitability.
Future P/E changed from 22.11x to 20.01x, pointing to a lower multiple that analysts are using when valuing the stock’s earnings.

2 views

Key Takeaways

Strategic restructuring, targeted innovation, and successful acquisitions are strengthening growth, operational efficiency, and diversification across premium and chronic care segments.
Expanding emerging market presence and user-focused product launches are driving recurring revenues, reducing regional dependence, and positioning Coloplast for sustained long-term momentum.
Intensifying pricing, regulatory, and currency pressures threaten Coloplast's revenue growth, margins, and brand reputation, amid operational risks and dependence on successful product innovation.

Catalysts

About Coloplast

Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally.What are the underlying business or industry changes driving this perspective?

The ongoing reorganization into distinct Chronic Care and Acute Care units, with a dedicated R&D function for Chronic Care, is designed to accelerate innovation cycles and improve time-to-market for new products. This is expected to drive higher revenue and operating margins by leveraging user-focused innovation and maximizing manufacturing efficiency.
Robust growth in Chronic Care segments-especially Ostomy and Continence Care-continues to be supported by increasing global incidence of chronic conditions and a growing elderly population, expanding the addressable market and providing a stable foundation for predictable, long-term revenue and earnings growth.
Successful integration and scaling of recent acquisitions like Kerecis, along with the merger of Advanced Wound Dressings and biologics, is expected to enhance Coloplast's competitive positioning in premium wound care markets, supporting margin expansion and revenue diversification as healthcare spending and quality-of-life-focused solutions see secular increases.
Proactive commercial investments in high-growth emerging markets, especially tender-based business in Asia, Eastern Europe, and Latin America, position Coloplast to capture above-market growth, further diversifying revenue streams and reducing over-reliance on mature European regions-likely leading to sustained multi-year revenue and earnings momentum.
The company's user-centric innovation, ongoing product launches (e.g., Luja, SenSura Mio, Provox Life), and pipeline progress (e.g., INTIBIA) are poised to benefit from the accelerating trend toward home-based healthcare and patient-managed solutions, supporting not only top-line growth but also higher recurring revenues and improved net margins over time.

Coloplast Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Coloplast's revenue will grow by 6.3% annually over the next 3 years.
Analysts assume that profit margins will increase from 14.3% today to 20.2% in 3 years time.
Analysts expect earnings to reach DKK 6.8 billion (and earnings per share of DKK 30.04) by about May 2029, up from DKK 4.0 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 20.0x on those 2029 earnings, down from 22.7x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 22.0x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.31%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The implementation of competitive bidding by CMS in the U.S. Chronic Care business could introduce significant pricing pressure starting as early as 2027, affecting approximately 6% of total group sales (50% of the 12% U.S. Chronic Care segment), with the potential for price reductions up to 30%, which would directly threaten revenue and compress net margins.
Regulatory complications and technical requirements unique to certain regions, such as China's strict local standards for wound dressings, have already triggered costly product returns (DKK 80 million impact in 2024-25 and ongoing headwinds into 2025-26), exposing Coloplast to recurring risks of sales interruptions and further negative impacts on revenue and earnings.
Ongoing and recurring product recalls, execution issues, and increasing regulatory scrutiny (both in Europe and China), pose risks to operational efficiency, brand reputation, and long-term profitability due to potential loss of market share to competitors and increased compliance costs.
Fluctuations in foreign exchange rates, particularly the depreciation of the U.S. dollar and emerging market currencies against the Danish krone, have negatively impacted reported revenues, and persistent currency volatility could continue to restrain revenue growth and earnings in future years.
The Acute Care segment is described as more volatile and dependent on innovation compared to the stable but slower-growing Chronic Care segment, implying that failure to deliver successful new launches or manage heightened R&D expenses could result in margin pressure, unpredictable earnings, and overall revenue volatility for the group.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of DKK500.15 for Coloplast based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK760.0, and the most bearish reporting a price target of just DKK380.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be DKK33.5 billion, earnings will come to DKK6.8 billion, and it would be trading on a PE ratio of 20.0x, assuming you use a discount rate of 6.3%.
Given the current share price of DKK402.7, the analyst price target of DKK500.15 is 19.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Coloplast?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

COLO B: Executive Team Changes And Chronic Care Strategy Will Drive Outperformance